{"id":"NCT01365052","sponsor":"Bayer","briefTitle":"Safety Trial of Naproxen Sodium/ Diphenhydramine","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Safety and Tolerability Trial of Naproxen Sodium/ Diphenhydramine Combination in an OTC Population","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2011-06-03","resultsPosted":"2014-06-16","lastUpdate":"2015-06-08"},"enrollment":326,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":null},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo (capsules containing no drug) when taken for 10 days.","primaryOutcome":{"measure":"Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product","timeFrame":"10 days after randomization","effectByArm":[{"arm":"Naproxen Sodium 440 mg/DPH 50 mg (BAY98-7111)","deltaMin":39.6,"sd":null},{"arm":"Placebo","deltaMin":45,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":217},"commonTop":["HEADACHE","SOMNOLENCE","BACK PAIN","NAUSEA","DIARRHOEA"]}}